Mesoporous catechin hydrogel for enhanced astaxanthin-based inflammatory bowel disease therapy Authors: Ningli Guo, Jiayi Shi, Xinyu Zhang, Hui Xu, Tongyao Ji, Fengkai Qiu, Kai Li, Zhenyi Wu, Ji Ma, Qiaoyou Weng, Rongfang Qiu, Gaofeng Shu, Zhang Chen, Jingfeng Chen, Xiaojing Wang Published: 2026 ABSTRACT AbstractInflammatory bowel disease (IBD) is a persistent intestinal inflammation driven by epithelial barrier dysfunction, immunological imbalance, and microbial dysbiosis. The restoration of gut homeostasis through biomaterial-based strategies offers a potential avenue for alleviating inflammation in IBD. Herein, an alginate-based hydrogel incorporating astaxanthin-loaded mesoporous catechin nanoparticles (AST@MCN-Gel) was designed to relieve inflammation and rebalance gut homeostasis. The mesoporous framework of MCN enabled effective encapsulation of the hydrophobic AST, thereby increasing its water solubility and bioavailability. In lipopolysaccharide-induced macrophages, AST@MCN exhibited superior ROS-scavenging capacity and anti-inflammatory activity relative to either AST or MCN. Mechanistically, AST@MCN modulated macrophage phenotype from pro-inflammatory (M1) to anti-inflammatory (M2) state through regulation of the MAPK/NF-κB pathway. On the other hand, the alginate-based hydrogel effectively enhanced the intestinal retention of AST@MCN, resulting in a marked improvement in oral therapeutic efficacy. In a DSS-induced IBD mouse model, oral administration of AST@MCN-Gel significantly alleviated the clinical symptoms and restored intestinal barrier integrity. Analysis of the gut microbiome further indicated that AST@MCN-Gel ameliorated gut dysbiosis by restoring microbial diversity and suppressing the proliferation of pathogenic species. Collectively, these underscore the potential of AST@MCN-Gel as an effective biomaterial-based therapeutic approach for restoring intestinal homeostasis and improving IBD therapy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-026-04665-y.Keywords: Inflammatory bowel disease, Astaxanthin, Mesoporous catechin nanoparticles, Macrophage polarization, Oxidative stress Introduction Inflammatory bowel disease (IBD)—a chronic and relapsing inflammatory condition of the gastrointestinal tract—encompasses two main clinical forms: Crohn’s disease (CD) and ulcerative colitis (UC), distinguished by immune dysregulation and persistent oxidative stress in the intestinal mucosa [1]. The global epidemiology of IBD has risen dramatically in recent decades, imposing substantial clinical and financial burdens [2]. Although standard therapies—such as aminosalicylates, corticosteroids, immunosuppressants, and biological drugs can induce and maintain remission in a proportion of patients, their long-term efficacy remains limited by incomplete response, loss of response, serious adverse effects (e.g., infection and malignancy risk), and high cost. Consequently, there remains a critical demand for safer, improved, and precisely selective therapeutic options [3]. Accumulating evidence indicates that IBD pathogenesis arises from a complex interplay among epithelial barrier dysfunction, dysregulated mucosal immunity and gut microbial dysbiosis. Increased intestinal epithelial barrier permeability facilitates the transfer of luminal antigens and bacteria, which in turn perpetuates immune activation and chronic inflammation. Concurrently, central to IBD pathogenesis is the aberrant activation of macrophages and their predominant shift to the pro-inflammatory M1 phenotype polarization in the inflamed mucosa [4]. M1 macrophages produce elevated levels of cytokines that promote inflammation, with prominent examples being TNF-α, IL-6, and IL-1β and generate an overproduction of reactive oxygen species (ROS) [5, 6], which exacerbate epithelial barrier disruption, perpetuate inflammation, and amplify tissue damage [7, 8]. In contrast, repolarization of macrophages to the anti-inflammatory M2 phenotype and efficient ROS scavenging can restore immune homeostasis, promote tissue repair, and attenuate disease progression [9]. Thus, simultaneous modulation of macrophage M1/M2 polarization and elimination of ROS represents a highly promising therapeutic avenue for IBD [10]. Naturally derived bioactive compounds possessing antioxidant and anti-inflammatory properties, have gained widespread attention for IBD management. Astaxanthin (AST), is one of the most potent natural antioxidants known, exhibiting ROS-scavenging capacity greater than that of vitamin C and α-tocopherol [11, 12]. AST exhibits potent anti-inflammatory activity, primarily by inhibiting the NF-κB signaling pathway and reducing the secretion of pro-inflammatory cytokines, and facilitation of M2 macrophage polarization [13, 14]. However, its translation to therapeutic use is hindered by poor water solubility, low oral bioavailability and limited intestinal retention, which markedly restrict therapeutic efficacy following oral administration. Nanotechnology‑based delivery systems provide a promising approach to overcome these barriers by enhancing drug solubility and stability while enabling targeted delivery to inflamed intestinal tissues, thereby significantly improving therapeutic efficacy [15–17]. Mesoporous nanomaterials exhibit remarkable advantages in the high-efficiency loading and stable delivery of hydrophobic small-molecule drugs due to their large specific surface area and precisely controllable hierarchical pore structure [18]. On the other hand, polyphenol-based biomaterials (e.g., catechin-derived nanostructures) inherently possess multiple biological activities including natural antioxidant, anti-inflammatory, and immunomodulatory properties [19], providing new insights for the construction of multifunctional delivery systems integrating carrier roles with therapeutic bioactivity [20–22]. Building upon these characteristics, mesoporous catechin nanoparticles (MCN) rich in phenolic hydroxyl groups could serve as a promising platform. Distinct from conventional inert drug carriers such as mesoporous silica and PLGA, such bioactive polyphenol-based mesoporous materials would inherently exhibit anti-inflammatory, antioxidant, and antibacterial activities, and could act synergistically with loaded AST to achieve combined therapeutic efficacy of the carrier and the drug for IBD treatment [23, 24]. Biomaterial‑based hydrogels have proven to be effective platforms for gastrointestinal drug delivery enabled by their biocompatibility, mucoadhesive properties, and capacity to prolong intestinal retention [25–27]. PH-responsive calcium-crosslinked sodium alginate hydrogels (Ca2+-ALG) are ideal for colon-specific delivery due to their gastric stability, disintegration in neutral-to-alkaline colonic pH [28, 29] and enhanced mucosal retention via electrostatic interactions, allowing for efficient and localized therapeutic delivery when combined with nanoparticles [30, 31]. This study presents an alginate‑based hydrogel containing astaxanthin‑loaded mesoporous catechin nanoparticles (AST@MCN-Gel) serving as a multifunctional oral therapeutic platform for IBD. The mesoporous catechin framework enabled efficient encapsulation of hydrophobic AST, improving its aqueous dispersibility and bioavailability, while providing inherent antioxidant activity. We hypothesized that the combined nanoparticle–hydrogel system would enhance intestinal retention, attenuate oxidative stress, modulate macrophage polarization via key inflammatory signaling pathways and ultimately restore gut homeostasis. Using in vitro macrophage models and a DSS-induced murine model of IBD, we systematically evaluated the anti‑inflammatory efficacy, barrier‑protective effects, and microbiota‑regulating capacity of AST@MCN‑Gel. Our findings demonstrate a promising biomaterial‑based strategy for IBD therapy through coordinated regulation of inflammation, immunity and the gut microenvironment (Scheme 1). Preparation of AST@MCN-Gel and its mechanism in treating IBD Materials and methods Materials Catechin (Cat. #: 225937-10-0) and Pluronic F-127 (Cat. #: 9003-11-6) were purchased from Sigma-Aldrich (USA). Astaxanthin (Cat. #: 472-61-7) was obtained from Yuanye Biotechnology (Shanghai, China). 1,3,5-Trimethylbenzene (Cat. #: 108-67-8) was obtained from Aladdin (Shanghai, China). DCFH-DA (Cat. #: HY-D0940), LPS (Cat. #: HY-D1056) and DiR (Cat. #: HY-D1048) were purchased from MedChemExpress (Shanghai, China). IFN-γ (Cat. #: AF-315-05) was obtained from Thermo Fisher Scientific (USA). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Cat. #: AS014) and goat anti-mouse IgG (Cat. #: AS003) were purchased from Abclonal (Wuhan, China). The CD86 antibody (Cat. #: 159204) and CD206 antibody (Cat. #: 141708) were provided by Biolegend (USA). The β-actin recombinant antibody (Cat. #: 81115-1-RR), Arg-1 antibody (Cat. #: 16001-1-AP), GAPDH monoclonal antibody (Cat. #: 60004-1-Ig), occludin mouse monoclonal antibody (Cat. #: 21865-1-AP), Phospho-NF-κB p65 (Ser468) recombinant monoclonal antibody (Cat. #: 82335-1-RR), NF-κB p65 polyclonal antibody (Cat. #: 10745-1-AP), ERK1/2 polyclonal Antibody (Cat. #: 11257-1-AP) and Phospho-ERK1/2 (Thr202/Tyr204) antibody were acquired from Proteintech (Wuhan, China). The anti-iNOS antibody (Cat. #: ab178945) was purchased from Abcam (USA), and DAPI staining solution (Cat. #: C0065) was sourced from Solarbio (Beijing, China). ZO-1 rabbit polyclonal antibody (Cat. #: AF8394) and claudin-1 rabbit polyclonal antibody (Cat. #: AF6504) were purchased from Beyotime Biotechnology (Shanghai, China). Additionally, the phospho-ERK1/2 (Thr202/Tyr204) antibody (Cat. #: AF1015) was purchased from Affinity Biosciences. All chemicals and reagents met analytical grade specifications and used without any additional purification steps. Cell lines and experimental animals The murine macrophage line RAW 264.7 (American Type Culture Collection, ATCC, USA) was cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, and incubated at 37 °C under a humidified atmosphere with 5% CO₂ environment. For M1-type macrophage polarization, cells were exposed to LPS (100 ng/mL) and IFN-γ (20 ng/mL) for 24 h. Male C57BL/6 mice aged 6 to 8 weeks, were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). All experiments involving animals were carried out in the Laboratory Animal Care and Use Guidelines of Lishui University, and approval was granted by the Institutional Animal Ethics Committee of Lishui University. (approval number 2025D159). Preparation of AST@MCN The preparation conducted following the method described in the literature. In brief, 100.0 mg of Pluronic F-127, 150.0 mg of catechin and 1000.0 mg of sodium chloride were dissolved in 40% ethanol solution. Following complete dissolution of the reactants, 150 µL of formaldehyde solution was introduced into the mixture, along with 1 mL of trimethylbenzene (TMB). The resulting solution was emulsified thoroughly and stirred for 30 min. Then, a volume of 400 µL ammonium hydroxide was introduced into the mixture via slow dropwise under continuous stirring, which was kept under these conditions for another 4 h. The final product was harvested by a 10-minute centrifugation at 12,000 rpm. followed by three washes using an ethanol–water mixture (1:1, v/v). The sample was stored at 4 °C until further use. Encapsulation efficiency and loading capacity To improve the drug-loading performance, a series of AST-to-MCN weight ratios (1:100, 2:100, 3:100, and 4:100) were systematically investigated. AST dissolution in DMSO was carried out to achieve a concentration of 2 mg/mL and then slowly added dropwise into the MCN dispersion while stirring was maintained. The mixture was stirred at room temperature for 15 min to allow adequate loading. Subsequently, the suspension following centrifugation at 1,000 rpm for 5 min to eliminate free, non-encapsulated AST. The harvested supernatant was subjected to additional centrifugation at 12,000 rpm for an additional 5 min to ensure complete separation of the encapsulated AST. AST encapsulation efficiency (EE) and loading capacity (LC) were assessed using a Shimadzu UV-1900i spectrophotometer, operating at a detection wavelength of 477 nm. The formulas used for the calculations are as follows: Characterization of AST@MCN Examination of the AST@MCN morphology was conducted via field-emission transmission electron microscopy (TEM, HT7800, Hitachi, Japan). Hydro dynamic diameter and zeta potential were performed by dynamic light scattering (DLS, Zeta sizer Lab ZSU3100, Malvern, UK). The UV–Vis absorption spectra were recorded using aUV-1900i spectrophotometer (Shimadzu, Japan). Samples were prepared by dispersing the materials in deionized water or DMSO to an appropriate concentration. Spectral data were collected between 200 and 800 nm; all measurements utilized quartz cuvettes with a 1 cm path length. Prior to each measurement, baseline correction was performed using the corresponding solvent as the reference. The positions and intensities of the absorption peaks were analyzed to identify the characteristic peaks of the free AST, MCN, and AST@MCN. Fourier transform infrared (FTIR) spectra were obtained using an IRSpirit-T spectrometer (Shimadzu, Japan) equipped with a KBr pellet accessory. Solid samples were thoroughly ground and used a mixture with spectroscopic-grade KBr in a 1:100 mass ratio approximately, followed by compression into transparent pellets via a hydraulic press. Measurement of spectra within the 4000–400 cm⁻¹ region was conducted. All spectral data were baseline-corrected and normalized using the LabSolutions IR software provided by the manufacturer. The characteristic absorption peaks were analyzed for the identification of functional groups and to confirm the presence of chemical interactions between AST and MCN. Release profile of AST@MCN The release characteristics of AST from AST@MCN were evaluated via a dialysis method. As the release medium, simulated intestinal fluid (SIF) was prepared using phosphate-buffered saline (PBS). AST@MCN was contained within a dialysis membrane with a molecular weight cut-off of 3500 Da (MD3525; Yuanye Biotechnology, Shanghai, China) and placed in the release medium. The setup was maintained at 37 °C with continuous shaking at 200 rpm. At specified time points (0, 1, 2, 4, 6, 8, 12, 24, 36, and 48 h), 1 mL of the external medium was withdrawn and replaced with an equal volume of fresh SIF to maintain sink conditions. The amount of released AST was quantified through absorbance measurements of the collected samples using UV–Vis spectrophotometry. Antioxidant capacity of AST@MCN DPPH and ABTS radical scavenging assays (Solarbio, Beijing, China) were employed to assess the antioxidant activity of AST@MCN. Free AST, MCN, and AST@MCN formulations were evaluated at varying AST concentrations achieved through incubation with the relevant working solutions. Following the reaction, measurements of absorbance were taken at 515 nm for DPPH and 405 nm for ABTS using UV–Vis. Radical scavenging efficiency was calculated as per the manufacturer’s guidelines. Evaluation of AST@MCN cellular uptake A total of 5 × 10⁵ RAW 264.7 cells were plated in each well of a 6-well plate and maintained under standard culture conditions for 24 h. The cells were then exposed to either free AST or AST@MCN at a concentration of 5 µg/mL. After incubation durations of 2, 4, or 6 h, three consecutive PBS washes were performed on the cells. Cellular uptake efficiency was investigated using two techniques: (1) flow cytometry (BD FACSCanto II, BD Biosciences, USA) to measure fluorescence intensity; (2) confocal laser scanning microscopy (CLSM, STELLARIS 5, Leica, Germany) for the observation of subcellular localization. In vitro cell viability assay The toxicity of AST@MCN in RAW264.7 cells was determined through the CCK-8 solution analysis. To allow cell attachment and growth, 8 × 10³ cells were seeded into each well of a 96-well plate and incubated for 24 h. Following incubation, the cells were treated with free AST, MCN, or AST@MCN at various concentrations (AST: (0, 5, 10, 20, 50, 75, 100, 125, 250, 500 µg/mL), with each concentration tested in triplicate. Following 24 h, each well was treated with 10% CCK-8 solution, followed by a 2-hour incubation at 37 °C. The absorbance at 450 nm was then measured using a microplate reader to assess cell viability. Measurement of antioxidant efficacy The efficacy of AST@MCN to scavenge ROS was measured utilizing the fluorescent probe DCFH-DA. We cultured RAW264.7 cells in 6-well plates at a concentration of 5 × 10⁵ cells per well and allowed them to adhere for 24 h. This was followed by stimulation using LPS (100 ng/mL) and IFN-γ (20 ng/mL) for another 24-hour period. Subsequent to stimulation, cells were exposed to AST, MCN, or AST@MCN (AST concentration: 5 µg/mL). After the designated treatment period, cells were exposed to 2 µM DCFH-DA diluted in PBS and incubated at 37 °C in the absence of light for 20 min and then washed thoroughly with PBS. ROS scavenging efficiency was assessed using two methods: (1) fluorescence microscopy to capture and quantify intracellular fluorescence signals, and (2) flow cytometry to detect ROS-associated fluorescence intensity, followed by quantitative analysis using ImageJ software. Determination of antioxidant enzyme activities and lipid peroxidation Catalase (CAT)(Solarbio, Beijing, China), superoxide dismutase (SOD)(Beyotime Biotechnology, Shanghai, China), and malon­dialdehyde (MDA)(Solarbio, Beijing, China) were detected in accordance with the biochemical kit . Regulatory effect of AST@MCN on ∆Ψm Impact of AST@MCN on the ∆Ψm in RAW 264.7 Cells was investigated using a dedicated fluorescent probe kit (Beyotime Biotechnology, Shanghai, China). For this experiment, cells were cultured for a 24-hour attachment period. After establishment of the inflammatory model as described in Sect. "Conclusion", and an additional 24-hour incubation with free AST, MCN, or AST@MCN (5 µg/mL AST), cells were stained with the JC-1 fluorescent probe at 37 °C for 30 min, following the manufacturer’s instructions, and subjected to two washes using JC-1 staining buffer. Changes in mitochondrial membrane potential were evaluated by using confocal laser scanning microscopy, and the quantitative analysis of fluorescence intensity was performed with ImageJ software. Investigation of AST@MCN effect of in vitro culture on macrophage polarization We seeded RAW264.7 cells into 6-well plates for in vitro culture. After establishment of the inflammatory model as described in Sect. “Measurement of antioxidant efficacy”, Cells were given treatment for 24 h. Afterward, cells were fixed in 4% paraformaldehyde, treated with 0.3% Triton-X100 for permeabilization, and incubated with 2% BSA for blocking to reduce non-specific binding cells were subsequently incubated with antibodies targeting CD86 and CD206 for immunostaining. The relative abundances of CD86-positive (M1) and CD206-positive (M2) macrophage subsets were quantified by flow cytometry, while the expression levels of iNOS (M1 marker) and Arg-1 (M2 marker) were visualized using CLSM. Western blot analysis The levels of expression for iNOS, P65, Arg-1, phosphorylated P65 (P-P65), ERK, and phosphorylated ERK (P-ERK) was evaluated by Western blot. Protease and phosphatase inhibitor-enriched RIPA buffer (1:100) was used to lyse the cells. Protein concentrations were determined by the Bradford method, using bovine serum albumin (BSA) as the standard. For SDS-PAGE, 10 µg of protein per sample was used for electrophoretic separation and transferred to a PVDF membrane. After blocking with 5% non-fat milk for1 hour at room temperature, the membranes were incubated overnight at 4 °C with the primary antibodies indicated as follows: anti-iNOS, anti-Arg-1, anti-P65, anti-phospho-P65 (P-P65), anti-ERK, and anti-phospho-ERK (P-ERK). After the washing step, membranes were incubated at room temperature for 2 h with HRP-conjugated secondary antibodies. Protein bands were visualized and analyzed using the Invitrogen iBright1500 gel imaging system (Thermo Fisher Scientific, USA). Cytokine quantification Enzyme-linked immunosorbent assay (ELISA) was employed to quantify pro-inflammatory cytokines, such as IL-6, IL-1β, TNF-α, and the anti-inflammatory cytokine IL-10. Seeding of RAW264.7 cells was performed in 6-well plates. Following the induction of inflammation as detailed in Sect. "Conclusion", M1-polarized macrophages were cultured in the presence of treatment (AST concentration: 5 µg/mL) for another 24 h. Following this, the culture supernatants were harvested, and the cytokine levels were determined with ELISA kits (Jiangsu MeiMian Industrial Co., Ltd., China) following the manufacturers’ instructions. Transcriptome profiling of AST@MCN-Treated inflammatory macrophages The RAW 264.7 macrophage cell line was maintained in a humidified incubator at 37 °C with 5% CO₂. Cells underwent random assignment to two groups: (1) a PBS control group treated with complete medium containing an equivalent volume of PBS; and (2) an AST@MCN treatment group exposed to AST@MCN at a final AST concentration of 5 µg/mL. In order to develop an in vitro inflammation model, both groups were co-stimulated with LPS and IFN-γ for 24 h. After stimulation, cells were washed three times with ice-cold PBS and total RNA was extracted using TRIzol™ reagent (Thermo Fisher Scientific, USA). RNA quality control, library construction, and sequencing were conducted by BGI. All experiments were carried out in biological triplicates. Differential gene expression was analyzed, and statistical significance was assigned to genes with an adjusted p-value less than 0.05. In vitro intestinal epithelial barrier function assessment Caco-2 cells were seeded into 12-well plates at a density of 5 × 10⁴ cells per well and cultured for 24 h. Subsequently, the cells were treated with LPS for 12 h, after which the medium was replaced with fresh serum-free medium containing AST@MCN, and the cells were further incubated for 48 h. Following the incubation, the cells were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.5% Triton X-100 for 20 min, and blocked with 5% bovine serum albumin for 30 min. The cells were then incubated overnight at 4℃ with a primary antibody mixture containing mouse anti-occludin polyclonal antibody (1:1000) and rabbit anti-ZO-1 polyclonal antibody (1:500). The next day, after three washes with PBS, the cells were incubated with fluorescent secondary antibodies (Alexa Fluor 488-conjugated goat anti-rabbit IgG, 1:1000; Alexa Fluor 488-conjugated goat anti-mouse IgG, 1:1000) for 1 h at room temperature in the dark. Following PBS washes, the nuclei were counterstained with DAPI (1 µg/mL) for 5 min. Finally, the cells were imaged using a confocal microscope. Characterization of physicochemical properties of hydrogels Macroscopic morphology observation (vial inversion method) The sol-gel phase transition behavior of Gel was qualitatively evaluated using the vial inversion method. The pre-gel solution was placed in an EP tube and incubated statically at 37 °C. The gelation state of the hydrogel was observed by inverting the tube. Micromorphology characterization The microporous structure of the hydrogel samples was observed using scanning electron microscopy (SEM). The fully crosslinked and cured hydrogel samples were flash-frozen in liquid nitrogen and freeze-dried. The cross-section of the hydrogel was then subjected to brittle fracture, and the fractured samples were sputter-coated with gold. Subsequently, the internal three-dimensional cross-linked network morphology, pore size structure, and pore distribution characteristics of the hydrogels were observed under SEM. Rheological property testing The time sweep test was carried out on a DHR-2 rheometer to record the storage modulus (G′) and loss modulus (G″) of the hydrogel. The measurement was performed at a fixed frequency of 1 Hz, with the strain ranging from 0.01% to 100%. In vitro degradation/release behavior A defined amount of cured AST@MCN-Gel was completely immersed in 10 mL of four different buffer media, namely SGF, SIF, SCF, and SCF + H2O2, and incubated statically at 37 °C. At predetermined time points, the residual gel was removed, wiped free of surface liquid, vacuum-dried to constant weight, and accurately weighed. The degradation rate of the hydrogel under different physiological and inflammatory microenvironments was calculated using the mass loss method. The drug release behavior of AST@MCN-Gel in different gastrointestinal media and inflammatory microenvironments was investigated using the dialysis bag method. A defined amount of AST@MCN-Gel was placed in a dialysis bag and then immersed in 10 mL of four media (SGF, SIF, SCF, and SCF + H2O2), followed by incubation at 37 °C with constant horizontal shaking. At set time intervals, samples were withdrawn, and an equal volume of fresh release medium was replenished. The cumulative release of AST was quantitatively determined using a UV-Vis spectrophotometer, and the cumulative release rate was calculated. In vivo spectral imaging Near-infrared fluorescent dye DiR was used as a probe, and an IVIS Spectrum in vivo imaging system (IVIS Lumina III, PerkinElmer, USA) was employed for fluorescence imaging and quantitative analysis to systematically investigate the in vivo drug release kinetics and tissue distribution characteristics of AST@MCN-Gel. After successfully inducing an acute IBD mouse model by administering drinking water containing 2.5% DSS, the mice were orally administered DiR-labeled DiR@MCN and DiR@MCN-Gel (DiR concentration: 2 mg/mL for both). To effectively remove unencapsulated free DiR, both formulations were subjected to three rounds of centrifugal washing, discarding the supernatant containing free probe after each centrifugation. Near-infrared fluorescence images were acquired in vivo at 2, 6, 12, 24, and 48 h post-administration. After the final imaging session, the mice were euthanized, and the colon tissues were harvested. The fluorescence intensity in the colon was semi-quantitatively analyzed using the IVIS system. Establishment and Treatment of IBD Model Following arrival, all mice were provided food and water during the acclimatization. An IBD model was established in 6–8 weeks male C57BL/6 mice using 2.5% DSS. A total of six groups were formed by random assignment of the mice (n = 5 per group): the control group (Normal), DSS model group (Model), blank carrier group (Gel), MCN-Gel group, AST-Gel group, and AST@MCN-Gel group, in order to investigate the treatment outcomes of the hydrogel on IBD. From day 8 onward, each mouse received a daily oral gavage of 100 µL of the respective formulation. The final AST concentration in the gavage formulation was 0.5325 mg/mL, which corresponded to a daily AST dose of 2.66 mg/kg body weight based on the administered gavage volume and average mouse body weight. On the final day of treatment, all animals were humanely euthanized. Cytokine analysis Blood samples were collected from the orbital venous plexus of mice under isoflurane anesthesia. The serum levels of TNF-α, IL-6, IL-1β, and IL-10 were measured using ELISA kits (Proteintech, Wuhan, China). Evaluation by histology and immunohistochemistry Two weeks post-experiment, euthanasia was performed on the mice following approved protocols, and gastrointestinal tissues were immersed in 4% paraformaldehyde (PFA). After dehydration, colon samples were embedded in paraffin, cut into 3–5 μm serial sections, and stained with hematoxylin and eosin (H&E) as well as periodic acid-Schiff (PAS) for histological assessment. Histopathological changes were observed under a light microscope. Histological scoring was evaluated according to the degrees of crypt damage, tissue edema and inflammatory cell infiltration. For immunofluorescence staining, sections were incubated with primary antibodies against iNOS, Arg-1, CD86, CD206, ZO-1, Occludin, and Claudin-1 (Beyotime Biotechnology, China), followed by incubation with appropriate fluorescently labeled secondary antibodies Alexa Fluor® 488 or 594 (goat anti-rabbit IgG). Safety evaluation To evaluate the in vivo biosafety profile of the treatment, mice were anesthetized and euthanized humanely Following the final treatment. Prior to euthanasia, blood samples were obtained by retro-orbital bleeding with capillary tube. The serum was separated by centrifugation (3000 rpm, 10 min, 4 °C) and key enzymatic markers, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and creatinine (CR), as well as Blood urea nitrogen (BUN) count were assessed to evaluate liver and kidney function. All serum biochemical parameters were analyzed by a certified third-party laboratory (Hangzhou Haoke Biotechnology Co., Ltd., Hangzhou, China). Key visceral organs are fully excised from each mouse, which included the heart, liver, spleen, lungs, and kidney rinsed in cold PBS, and immediately fixed in 4% paraformaldehyde (PFA). Following fixation, tissues underwent conventional processing, were embedded in paraffin and cut into 5 μm slices. Subsequent staining with hematoxylin and eosin (H&E) enabled histopathological evaluation. The histopathological evaluation was performed from Hangzhou Haoke Biotechnology Co.,Ltd. Gut microbiota analysis To assess the impact of AST@MCN-Gel treatment on gut microbiota composition, 16 S rRNA gene sequencing of fecal samples was performed. The hypervariable region of the 16 S rRNA gene that was sequenced was the V3-V4 region. Sequencing was performed on the NovaSeq 6000 (Illumina) platform. Raw reads were processed using the QIIME2 (version 2023.2) pipeline with DADA2 for denoising, quality filtering, and amplicon sequence variant inference. Taxonomic assignment was performed against the Silva 138.1 reference database. Subsequent analyses of alpha diversity, beta diversity, and community differences were all conducted based on the above analytical pipeline. C57BL/6 mice were randomly assigned to one of three experimental cohorts (n = 5): (1) a healthy control group; (2) a DSS-induced IBD model group, in which acute IBD was established by exposing to 2.5% DSS dissolved in drinking water over a 7-day period; and (3) following a 7-day induction period of acute colitis via 3% DSS in drinking water, mice in the AST@MCN-Gel group, in which administration (100 µL per day) via oral gavage. On experimental day 10, all mice were subjected to aseptic collection of freshly excreted fecal samples and immediately preserved at -80℃ until further analysis. The process was completed in Luo Xi Biotechnology Co., Ltd. (Hangzhou, China). Statistical analysis Values represent mean ± standard deviation (SD). The normality of data distribution was evaluated using the Shapiro-Wilk test. For datasets that followed a normal distribution, comparisons between two groups were performed with the Student’s t-test. Comparisons involving a single factor were analyzed using one-way ANOVA, whereas data involving two independent variables were analyzed by two-way ANOVA, followed by Dunnett’s post-hoc test for comparisons with the control group. In cases where data were not normally distributed, non-parametric tests were employed: the Mann-Whitney U test for two-group comparisons and the Kruskal-Wallis test for multiple groups (GraphPad Prism 10.0, USA). A p-value < 0.05 was considered statistically significant, denoted as *p < 0.05, **p < 0.01, and ***p < 0.001. Results and discussion Synthesis and characterization of AST@MCN Over the past few years, mesoporous nanomaterials have received extensive focus on drug carriers because of their size-tailorable particles, structurally adjustable mesopores, and high specific surface area [32–35]. In this study, catechin was used as a polyphenolic crosslinking monomer. Catechin molecules achieved ordered adsorption and directed assembly on the surface of Pluronic F127 micelles through hydrogen bonding, hydrophobic interactions, and π-π stacking effects. Under alkaline conditions, catechin underwent phenolic condensation with formaldehyde to construct a three-dimensional organic polymer framework [36]. The size of the F127 micelles was tuned by toluene swelling and NaCl salting-out effects. After complete curing of the crosslinked system, the Pluronic F127 soft template was removed, yielding mesoporous materials with ordered pore structures (Fig. 1A). TEM analysis revealed that the synthesized MCN exhibited a uniform spherical morphology with an average diameter of approximately 150 nm and small pores distributed on the surface (Fig. 1B). The nitrogen adsorption-desorption isotherm (Figure S1) displayed a typical hysteresis loop characteristic of mesoporous materials, and the pore size distribution analysis confirmed the presence of uniform open mesopores with a diameter of about 15 nm (Figure S2), along with a specific surface area of approximately 97.4 m2/g. Subsequently, MCN loaded with astaxanthin (AST@MCN) were prepared via a solvent diffusion method. Further confirmation from TEM images showed that AST@MCN made up of nanoparticles exhibiting uniform size and spherical shape. In contrast, AST@MCN did not exhibit clear mesoporous features, presumably resulting from the adsorption of astaxanthin onto the MCN’s pores. Thanks architecture and substantial surface area of MCN, the ratio of astaxanthin to MCN was determined to be 2:100 by optimizing the drug-loading proportion. Under these conditions, the loading of the drug and the efficiency of encapsulation were found to be 2.13 ± 0.29% and 99.3 ± 0.36%, respectively (Fig. 1C and D). Dynamic light scattering (DLS) analysis indicated that the average sizes of MCN and AST@MCN were 155.8 ± 1.95 nm and 173.36 ± 1.85 nm, respectively (Fig. 1E). In PBS, the ζ-potential values for MCN and AST@MCN were − 23.9 mV and − 26.5 mV, respectively (Fig. 1F). The ultraviolet-visible (UV-Vis) spectroscopic assessment indicated an absorption feature typical of free astaxanthin at 477 nm, while AST@MCN did not show significant absorption at this wavelength (Fig. 1G), which could be attributed to hydrogen bonding associations involving astaxanthin and MCN. Fourier-transform infrared (FT-IR) analysis further validated this phenomenon, along with the free astaxanthin showing a characteristic unsaturated alkyl stretching vibration peak at 3060 cm− 1 (Fig. 1H). Figure 1I illustrates the pH-dependent release behavior of AST@MCN in SGF, SIF, and SCF. A burst release was observed in the acidic gastric environment (SGF, pH 1.2), whereas the release was substantially retarded under neutral to slightly alkaline intestinal/colonic conditions. Additionally, the stability of AST@MCN was evaluated. Due to the strong hydrophobicity of AST, free AST rapidly aggregated and precipitated in aqueous solution. In contrast, after encapsulation with MCN, AST@MCN exhibited no obvious precipitation within 5 days (Figure S3), indicating that MCN loading substantially enhances the stability of AST, thereby favoring improved delivery performance and bioavailability. Preparation and characterization of AST@MCN. A) Schematic diagram of AST@MCN synthesis. B) TEM images of MCN and AST@MCN. C) Drug loading capacity and D) Encapsulation efficiency of AST in AST@MCN. E) Average particle size and F) Zeta potential of MCN and AST@MCN. G) UV-Vis absorption spectrum of AST, MCN, and AST@MCN. H) FT-IR spectrum of AST, MCN, and AST@MCN. I) The release rates of AST@MCN in SGF, SIF, SCF and SCF + H2O2. J-M) Free radical scavenging capacity of AST@MCN against ABST and DPPH at different concentrations. Data are presented as mean ± standard deviation (SD) (n = 3, independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001 The antioxidant activity of AST@MCN was measured by performing 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging assays. The clearance rate exhibits concentration dependence and results demonstrated that AST@MCN at 20 µg/mL exhibited the ability to almost completely scavenge both DPPH· and ABTS· radicals (Fig. 1J and M), indicating its excellent anti-radical activity, indicating its promise for use as an effective antioxidant. AST@MCN prevents oxidative damage in macrophages AST@MCN exhibited pronounced antioxidant activity in vitro, highlighting its strong potential for ROS scavenging (Fig. 2A). The internalization of AST@MCN by RAW 264.7 macrophages was first examined by CLSM, revealing a time-dependent increase in intracellular fluorescence from 2 h to 6 h (Fig. 2B and C). After confirming efficient cellular uptake, we evaluated the cytotoxicity of AST@MCN. Neither free AST nor the MCN carrier exhibited significant concentration-dependent cytotoxicity (Figure S4-S5), and AST@MCN showed no detectable cytotoxic effects across the tested concentration range (Fig. 2D). Collectively, these results demonstrate that AST@MCN is readily internalized by RAW 264.7 macrophages without compromising cell viability, highlighting its excellent biocompatibility for further applications. In vitro antioxidant activity of AST@MCN. A) Schematic diagram of the antioxidant mechanism of AST@MCN. B-C) Cellular internalization of AST and AST-MCN in Raw264.7 Cells. D) Cytotoxicity of AST@MCN at Different Concentrations (0–500 µg/mL). E-F) Intracellular ROS scavenging capacity of AST@MCN and G) Flow cytometric quantification. H-J) Expression levels of MDA, SOD and CAT. K-L) The variations of mitochondrial membrane potential. Data are presented as mean ± SD (n = 3, independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001 To explore the cytoprotective effects of AST@MCN under oxidative stress conditions, intracellular ROS accumulation was induced in macrophages by co-stimulation exposed to lipopolysaccharide (LPS) and interferon-γ (IFN-γ), followed by treatment of the cells with AST@MCN. Then, the intracellular ROS scavenging capacity of AST@MCN was measured employing the DCFH-DA indicator. Fluorescence microscopy revealed that macrophages subjected to LPS + IFN-γ stimulation exhibited strong green fluorescence, with an intensity of 46.174% ± 13.45%. In contrast, treatment with free AST or MCN markedly attenuated intracellular fluorescence, reducing the intensity to 24.69% ± 3.96% and 26.46% ± 4.15%, respectively (Fig. 2E and G). These results indicate either AST or MCN could effectively suppress the increase in intracellular ROS. Interestingly, the AST@MCN-treated macrophages showed the most significant decrease in green fluorescence intensity (6.127%±2.40%), demonstrating an increased ROS levels scavenging ability. These observations were corroborated by quantitative flow cytometry analysis and demonstrated that AST@MCN exhibited the strongest ROS scavenging capacity among all treatment groups. In addition, the effects of AST@MCN on other biomarkers for oxidative stress, such as catalase (CAT), superoxide dismutase (SOD), and malondialdehyde (MDA), were further evaluated. As shown in Fig. 2H and J, exposure to LPS combined with IFN-γ induced a marked decrease in CAT and SOD activities, accompanied by a significant increase in MDA levels. Following 24 h of pre-incubation with AST@MCN, CAT and SOD levels were significantly restored, while MDA levels were markedly reduced in comparison to the other treatment groups. Overall, these confirm that AST@MCN possesses superior antioxidative potency and alleviates oxidative stress in vitro. Mitochondrial reactive oxygen species contribute significantly to a diminished mitochondrial membrane potential (∆Ψm) is recognized as an early hallmark of apoptotic progression [37, 38]. For the purpose of analyzing the outcomes of AST@MCN on mitochondrial activity, changes in ∆Ψm in macrophages were evaluated utilizing JC-1 staining. JC-1 is a widely used fluorescent probe whose emission properties depend on ΔΨm: under high membrane potential, JC-1 aggregates in mitochondria in the form of J-aggregates, producing red fluorescence, while the reduction of ΔΨm results in JC-1 existing as monomers that emit green fluorescence. Accordingly, a red-to-green fluorescence shift indicates mitochondrial depolarization and early apoptosis. CLSM Experimental outcomes demonstrated that the blank group exhibited differences when compared to macrophages treated with LPS + IFN-γ displayed markedly reduced red fluorescence accompanied by intensified green fluorescence, reflecting a significant loss of ∆Ψm (Fig. 2K and L). Treatment with free AST or MCN partially restored ΔΨm, as evidenced by a moderate recovery of red fluorescence and a reduction in green fluorescence. Notably, the AST@MCN treatment group exhibited a pronounced decrease in green fluorescence accompanied by a substantial restoration of red fluorescence, indicating that AST@MCN could better protect ΔΨm at a normal level. Collectively, AST@MCN exhibited robust protective effects by scavenging excessive ROS, preserving mitochondrial function and protecting ΔΨm at a normal level. The data support the hypothesis that the prospective therapeutic value of AST@MCN. In vitro anti-inflammatory effects analysis Macrophages play a crucial role in the initiation and continuation of intestinal inflammation in IBD, owing to their remarkable plasticity and capacity to adopt distinct functional phenotypes in response to microenvironmental cues [39]. During inflammatory conditions, macrophages often preferentially adopt the classically activated M1 phenotype, characterized by the upregulation of surface markers like CD86 and an overproduction of pro-inflammatory mediators. This polarization intensifies mucosal inflammation and contributes to tissue injury. Conversely, alternatively activated M2 macrophages contribute to inflammation resolution and tissue repair through anti-inflammatory signaling. Accumulating evidence indicates that an imbalance favoring M1 polarization over M2 polarization is a key immunopathological feature of IBD and closely correlates with disease severity [40, 41]. Therefore, therapeutic strategies capable of reprogramming the polarization of macrophages to an anti-inflammatory M2 phenotype represent a promising approach for restoring intestinal immune homeostasis [42]. To further explore the underlying macrophage polarization, an investigation was conducted to assess the impact of AST@MCN on macrophage polarization in vitro. LPS and IFN-γ were used to stimulate RAW 264.7 cells, inducing M1 macrophage activation (Fig. 3A). CLSM imaging revealed that AST@MCN treatment markedly reduced the iNOS fluorescence signal, an indicator of M1 macrophage polarization, while also promoting the expression of the M2 marker Arg-1, indicating a phenotypic shift from M1 toward M2 polarization (Fig. 3B and D). Flow cytometry analysis revealed a marked suppression of CD86 expression following AST@MCN treatment, with levels reduced to 28.4% ± 6.22%, whereas the LPS + IFN-γ group exhibited a substantially higher proportion at 74.9% ± 0.36% (Fig. 3E and G). In comparison, free astaxanthin and MCN alone showed moderate effects, yielding CD86 expression levels of 39.2% ± 0.66% and 57.13% ± 2.40%, respectively. In parallel, M2 macrophage polarization was enhanced across treatment groups, with percentages increased to 41.43% ± 0.65% for free AST, 55.06% ± 1.05% for MCN, and 64.8% ± 2.79% for AST@MCN (Fig. 3E and G). Consistently, the observations were further substantiated by Western blot analysis, demonstrating significant reduction of iNOS and upregulation of Arg-1 following AST@MCN treatment, with effects superior to those of free astaxanthin or MCN alone (Fig. 3H). In vitro immunomodulatory and anti-inflammatory properties of AST@MCN. A) Schematic diagram of the immunomodulatory and anti-inflammatory mechanism of AST@MCN. B) Representative confocal microscopy images of M1-type (iNOS) and M2-type (Arg-1) macrophages following different treatment and C-D) Quantitative Analysis. E) Flow Cytometric Analysis and F-G) Quantification of CD86 and CD206 expression in macrophages following various treatment. H) Protein expression levels of iNOS and Arg-1 in activated macrophages following various treatment. I-L) ELISA determination of TNF-α, IL-1β, IL-10 and IL-6 levels in activated macrophages following various treatment. Data are presented as mean ± SD (n = 3, independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001 Chronic dysregulated intestinal inflammation is a central driver of IBD progression. This persistent inflammatory state is maintained by overproduction of key inflammatory mediators, particularly TNF-α, IL-1β, and IL-6, which disrupt epithelial barrier integrity and activate innate immune responses [43]. Concurrently, impaired anti-inflammatory signaling mediated by IL-10 further exacerbates the disparity between pro-inflammatory and anti-inflammatory signaling pathways. This cytokine dysregulation forms an injury that sustains itself, ultimately leading to IBD, including mucosal damage and immune cell infiltration. Accordingly, restoring cytokine homeostasis has become a key therapeutic strategy for IBD. The effect of these treatments on cytokine production was further assessed by enzyme-linked immunosorbent. The results showed that both free AST and MCN inhibited the expression of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, whereas IL-10 production was significantly promoted, but their effects were not as potent as those observed in the AST@MCN treatment group (Fig. 3I and L). In addition, in the Caco-2 cell model, AST@MCN significantly reversed LPS-induced downregulation of the tight junction proteins Occludin and ZO-1, exhibiting superior effects compared to free AST or MCN alone (Figure S6). Collectively, AST@MCN promotes the polarization transition of macrophages from the M1 to M2 phenotype, restores cytokine homeostasis, and repairs the intestinal epithelial barrier, thereby offering a promising comprehensive therapeutic strategy for IBD. AST@MCN suppresses macrophage-mediated inflammation through modulation of the MAPK/NF-κB inflammasome pathway To further elucidate the anti-inflammatory mechanism of AST@MCN, we performed RNA sequencing on LPS-stimulated M1 macrophages treated with either PBS or AST@MCN. Transcriptomic analysis revealed a total of 13,735 genes co-expressed in both experimental groups, including 866 genes unique to the PBS group and 833 genes unique to the AST@MCN group (Fig. 4A). A total of 793 genes with differential expression were identified across the two groups, comprising 387 upregulated genes and 406 downregulated genes (Fig. 4B). To assess the signaling pathways that may be modulated by AST@MCN, we conducted a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The results displayed significant enrichment in the p53 signaling pathway, TNF signaling pathway, and NOD-like receptor signaling pathway, which closely associated with the anti-oxidative and anti-inflammatory effects of AST@MCN (Fig. 4C). Furthermore, heatmap analysis demonstrated prominent downregulation of genes related to the MAPK signaling pathway in AST@MCN-treated M1 macrophages (Fig. 4D). Anti-inflammatory mechanism of AST@MCN. A) Venn diagram of transcriptomic profiles between G2 and G5. B) Volcano plot of differentially expressed genes (DEGs) (Red dots denote significantly up-regulated genes, blue dots denote significantly down-regulated genes, and gray dots represent non-significant genes). C) Bubble plot of KEGG pathway enrichment analysis. D) Heatmap of DEGs related to the MAPK signaling pathway. E) Gene Ontology (GO) enrichment analysis (Molecular Function category). F) Gene set enrichment analysis (GSEA) plot for the MAPK signaling pathway. G-J) Validation of key MAPK and NFκB pathway protein expression by Western Blot. Data are presented as mean ± SD (n = 3, independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001 To achieve a deeper understanding of the biological functions influenced by AST@MCN concerning differentially expressed genes (DEGs) associated with IBD, we conducted Gene Ontology (GO) enrichment analysis. This analysis included three principal categories: cellular component, molecular function, and biological process. In the cellular component category (Figure S7), the DEGs were significantly enriched in membrane receptor complexes involved in immune recognition (e.g., Toll-like receptor complexes, IL-6 receptor complexes, and CD40 receptor complexes) as well as key nuclear complexes that regulate inflammatory signal transduction. These findings suggest that AST@MCN directly modulates immune cell activation and the initiation/propagation of inflammatory signaling. In the molecular function category (Fig. 4E), the DEGs were highly enriched for proteins exhibiting NF-κB binding, tumor necrosis factor receptor binding, cytokine binding, and MAP kinase kinase activities, further confirming their central position within the inflammatory signaling network at the molecular interaction level. The most striking results emerged from the biological process category (Figure S8), where the DEGs were most significantly enriched in pathways including positive regulation of lipopolysaccharide-mediated signaling, positive regulation of inflammatory response, positive regulation of tumor necrosis factor production, positive regulation of NF-κB signaling pathway, enhancement of T cell proliferation, and positive modulation of macrophage activation. Notably, modulation of autophagy — a process critical for cellular homeostasis in IBD — was also significantly enriched [44]. Furthermore, gene set enrichment analysis (GSEA) showed that the overall expression of MAPK pathway-related genes was significantly downregulated in M1 macrophages after AST@MCN treatment (Fig. 4F). These findings collectively suggest that AST@MCN exerts prominent regulatory effects on the MAPK and NF-κB signaling pathways. To further verify this regulatory pattern and clarify how AST@MCN modulates inflammatory signaling, we detected the phosphorylation levels of ERK and p65 — two core downstream molecules of the MAPK/NF-κB cascade [40] — via Western blot. Meanwhile, the ERK inhibitor U0126 and NF-κB inhibitor BAY 11-7082 were further applied for mechanistic validation. The results showed that compared with the LPS-induced inflammatory model group, AST@MCN markedly downregulated the phosphorylation levels of ERK and p65. Individual treatment with U0126 or BAY 11-7082 also significantly inhibited the activation of the corresponding pathway proteins. Notably, after specific blockage of the target pathways via inhibitor pretreatment, additional administration of AST@MCN failed to exert any further inhibitory effects. No significant statistical difference was observed between the single inhibitor group and the combined treatment group (Figs. 4G-J). These findings demonstrate that specific blockade of the MAPK or NF-κB signaling pathway abolishes the additional regulatory effects of AST@MCN. Collectively, combined with transcriptome sequencing analysis, detection of key phosphorylated proteins, and functional rescue assay, we confirmed that AST@MCN exerts its therapeutic effects mainly by suppressing the activation of the MAPK/NF-κB signaling pathway. Characterization and in vivo distribution of AST@MCN-Gel For convenient oral and gastrointestinal administration, AST@MCN was encapsulated within a sodium alginate matrix to form an AST@MCN-Gel system (Fig. 5A). The freeze-dried AST@MCN-Gel was analyzed by scanning electron microscopy (SEM) (Fig. 5B). The AST@MCN-Gel exhibits a typical three-dimensional interconnected porous architecture, which is favorable for rapid fluid diffusion and mass transport. Notably, the pore walls consist of dense and wrinkled lamellar sheets, indicating a well-developed crosslinked network. The gelation behavior of AST@MCN-Gel before and after Ca2+ introduction was visually assessed by an inverted vial test (Fig. 5C). Upon the addition of Ca2+, the ALG solution rapidly transformed into a self-supporting AST@MCN-Gel that remained completely immobile under inverted conditions (left panel), demonstrating excellent mechanical integrity. This phenomenon is responsible for the development of a three-dimensional “egg-box” crosslinking structure resulting from ionic coordination between Ca2+ and guluronic acid blocks of ALG chains. In contrast, the pure ALG solution without Ca2+ exhibited rapid flow upon inversion (right panel), owing to the unrestricted mobility of its linear polymer chains and the absence of an effective crosslinked network. Rheological time sweep results showed that at the initial stage, the storage modulus (G′) was lower than the loss modulus (G″), indicating a predominantly viscous fluid-like behavior. As the test progressed, the two moduli intersected at approximately 75 s (Gel point), marking the sol–gel transition (Fig. 5D). After the transition, G′ became significantly higher than G″, suggesting the gradual formation of a continuous gel network. Furthermore, frequency sweep results (Figure S9) revealed that G′ remained consistently higher than G″ across the entire tested frequency range, with no crossover observed. These findings confirm that the hydrogel exhibits a typical elastic-dominated behavior and possesses a structurally stable three-dimensional crosslinked network. Notably, hydrogel degradation and drug release experiments demonstrated that AST@MCN-Gel remained structurally stable and exhibited slow degradation in SGF, effectively preventing the premature and rapid release of AST@MCN and thereby protecting the drug from loss during gastric transit. In contrast, under SCF conditions, the hydrogel exhibited an increased degradation rate accompanied by a moderately accelerated drug release, indicating that this system possesses favorable colon-responsive release characteristics and potential for colon-targeted delivery (Figures S10, S11). Furthermore, the inflammatory microenvironment simulated by H2O2 did not significantly alter the release rate of the hydrogel. This pH-responsive behavior is attributed to the structural dynamics of the alginate/Ca2+ hydrogel. In the acidic SGF, the carboxyl groups (–COOH) of alginate become protonated, which significantly weakens their electrostatic interactions with Ca2+ ions, leading to a decrease in crosslinking density. At the same time, dense hydrogen bonds form between the polymer chains, causing the gel network to transform from a loose ionically crosslinked network into a dense, contracted alginic acid gel layer, thereby slowing down and restricting drug release. In near-neutral to slightly alkaline SIF/SCF, the carboxyl groups deprotonate to -COO−, providing abundant binding sites for Ca2+ and thereby stabilizing the gel network; however, the strong electrostatic repulsion among the negatively charged polymer chains simultaneously causes the network to swell. The enlarged mesh size promotes gel swelling, thereby accelerating drug release. Characterization and in vivo distribution of AST@MCN-Gel. A) Schematic representation of the preparation of AST@MCN-Gel. B) Representative SEM image of AST@MCN-Gel. C) Visualization of hydrogel gelation using EP tubes. D) Time sweep curve of the Gel (storage modulus G’, loss modulus G’’). E) Ex vivo gastrointestinal fluorescence imaging of free DiR, DiR@MCN, and DiR@MCN-gel in DSS-induced IBD Mice. F-H) Quantitative analysis of the fluorescence intensity. Data are presented as mean ± SD (n = 3, independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001) To further evaluate whether AST@MCN could delay the progression of IBD, we first conducted an in vivo biodistribution using the near-infrared fluorescent dye 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR). DiR was encapsulated into MCN to serve as a fluorescent surrogate, enabling noninvasive tracking of AST@MCN retention following oral administration. The resulting DiR-loaded formulation was subsequently incorporated into the alginate-based hydrogel to form DiR@MCN-Gel. After oral gavage, fluorescence signals were recorded at predetermined time points using an IVIS imaging system to monitor gastrointestinal distribution, targeting efficiency, and retention behavior in vivo. As shown in Fig. 5E and H, in a DSS-induced mouse model of IBD, the DiR@MCN-Gel exhibited significantly enhanced targeting accumulation and prolonged intestinal retention time in the gastrointestinal tract compared with free DIR and DIR@MCN. This favorable in vivo biodistribution profile indicates that encapsulation of the drug into the Gel effectively improves its oral bioavailability, enhances intestinal mucoadhesive properties, and achieves targeted enrichment of the drug at colonic inflammatory lesions. Oral administration of AST@MCN-Gel Reduces the severity of DSS-induced IBD in vivo IBD is an immune-mediated disorder of the gastrointestinal tract, distinguished by persistent mucosal injury, epithelial barrier disruption, and severe inflammatory responses. To comprehensively assess the therapeutic efficacy of AST@MCN-Gel for IBD mouse model was established, which recapitulates key pathological features of human IBD, including mucosal injury, immune dysregulation and inflammatory cytokine overproduction [45]. The experimental scheme is shown in Fig. 6A. Mice were randomly divided into six groups: healthy control, DSS, DSS + Gel, DSS + AST-Gel, DSS + MCN-Gel, and DSS + AST@MCN-Gel. IBD was induced by DSS administration for 7 days, followed by 7 days of oral treatment. Therapeutic efficacy of AST@MCN-Gel in IBD. A) Schematic illustration of the experimental design. B) Body weight and C) DAI score. D) Quantitative analysis of colon lengths. E-F) Representative photographs of mouse colons and spleens following various treatment. G-H) Spleen and liver index in mice. I) Myeloperoxidase (MPO) activity in colon tissues. J-K) H&E and periodic acid-Schiff (PAS) staining of colon tissue sections. L-O) Serum levels of cytokines TNF-α, IL-1β, IL-6, and IL-10. Data are presented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 To evaluate disease severity and therapeutic response, multiple clinical, biochemical, and histological parameters were systematically analyzed. Body weight change and disease activity index (DAI) were further assessed to monitor clinical symptoms of IBD progression. DSS-treated mice exhibited continuous body weight loss and elevated DAI scores, reflecting severe diarrhea, fecal bleeding, and systemic deterioration (Fig. 6B and C). Colon length, a sensitive macroscopic indicator of intestinal inflammation and tissue damage in IBD, was markedly shortened after DSS induction (3.1 ± 0.92 cm) compared with healthy mice (8.3 ± 0.85 cm) (Fig. 6D). In contrast, treatment with AST@MCN-Gel significantly restored colon length to 7.5 ± 0.56 cm, approaching normal levels and outperforming free AST and MCN, indicating effective protection against DSS-induced intestinal injury (Fig. 6E). Notably, oral administration of AST@MCN-Gel markedly attenuated weight loss and significantly reduced DAI scores, demonstrating superior efficacy in alleviating IBD-associated clinical manifestations. DSS-induced IBD triggered systemic immune activation, as evidenced by splenomegaly [46, 47]. The spleen index increased dramatically from 2.3 to 7.43 following DSS treatment (Fig. 6F and H). Importantly, AST@MCN-Gel markedly reduced spleen enlargement, restoring spleen weight toward physiological levels and indicating attenuation of excessive immune activation. Moreover, given that neutrophil infiltration is a hallmark of active IBD, colonic myeloperoxidase (MPO) activity was quantified as an indicator of inflammatory cell recruitment. DSS exposure resulted in a pronounced increase in MPO activity, whereas AST@MCN-Gel treatment significantly suppressed MPO levels (Fig. 6I), suggesting effective inhibition of neutrophil-driven inflammation. Histopathological analysis further confirmed the protective effect of AST@MCN-Gel on intestinal tissue structure. H&E staining revealed that mice in the DSS model group exhibited severe disruption of colonic epithelial integrity, characterized by typical pathological features such as disorganized crypt architecture and extensive inflammatory cell infiltration in the mucosal layer, accompanied by a significantly elevated histological score, confirming substantial damage to the intestinal mucosal barrier. In contrast, the AST@MCN-Gel treatment group maintained intact colonic epithelial structure, showed markedly reduced inflammatory cell infiltration, and presented a significantly decreased tissue damage score. PAS staining further demonstrated obvious goblet cell depletion in the DSS group (Figs. 6J-K, Figure S12). Of note, compared with free AST or MCN alone groups, AST@MCN-Gel more effectively repaired damaged intestinal tissue and ameliorated colonic pathological injury, exhibiting superior protective and restorative capacity for the intestinal mucosa. The in vivo anti-inflammatory effects of AST@MCN-Gel were validated by immunofluorescence staining and cytokine quantification in colonic tissues. AST@MCN-Gel treatment significantly suppressed M1-type macrophage polarization (CD86/iNOS-positive) while promoting M2-type polarization (CD206/Arg-1-positive) (Figure. S13). In addition, the levels of pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 were significantly upregulated in the serum of DSS-induced IBD mice (Fig. 6L and N), while AST@MCN-Gel treatment effectively reduced their levels. Meanwhile, the anti-inflammatory cytokine IL-10 was significantly elevated in the AST@MCN-Gel-treated group (Figure. 6O). Collectively, these results demonstrate that AST@MCN-Gel exhibits potent immunomodulatory and anti-inflammatory properties in vivo, highlighting its potential as an effective therapeutic agent for IBD. Therapeutic effect of AST@MCN-Gel on intestinal barrier integrity To evaluate the restorative effect of AST@MCN-Gel on intestinal barrier function, we assessed the expression levels of key tight junction proteins in colonic tissues. As shown in the Fig. 7A and B, compared with the control group, the expression of Occludin and ZO-1 was significantly decreased in DSS-induced model mice. After treatment with AST@MCN-Gel, the expression of both proteins was markedly upregulated, returning to near-normal levels. Furthermore, the expression of the tight junction protein Claudin-1 was also significantly increased in the treatment group (Fig. 7C and E). These results indicate that AST@MCN-Gel can effectively promote the expression of intestinal barrier-related proteins and enhance the integrity of the mucosal physical and chemical barrier, which may represent one of the key mechanisms underlying its therapeutic effect against IBD. Therapeutic effect of AST@MCN-Gel on intestinal barrier integrity. A) Representative immunofluorescence images of Claudin-1 expression levels in colonic tissues from different mouse groups. B) Representative immunofluorescence images of Occludin and ZO-1 expression levels in colon tissues from different mouse groups. C) Analysis of fluorescence intensity of Claudin-1. D) Occludin, and E) ZO-1 (n = 5). Data are presented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 After confirming AST@MCN-Gel in alleviating DSS-induced IBD, the in vivo biosafety and tissue distribution were further evaluated to assess its translational potential. Serum biochemical analyses were performed to examine potential hepatic and renal toxicity. As shown in Figure S14, key liver function markers, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as renal function indicators, blood urea nitrogen (BUN) and creatinine (CREA), remained within normal physiological ranges in AST@MCN-Gel–treated mice. These results indicate that oral administration of AST@MCN-Gel does not induce detectable hepatic or renal dysfunction, demonstrating favorable systemic biocompatibility. To further investigate the in vivo distribution and organ exposure of the formulation, DiR-labeled DiR@MCN-Gel was orally administered, and fluorescence signals were monitored 48 h after gavage. As shown in Figure S15, no obvious DiR fluorescence signals were observed in major visceral organs, including the heart, liver, spleen, lung, and kidney, whereas strong fluorescence signals were mainly retained within the intestinal lumen. These results indicate that the DiR-labeled AST@MCN-Gel exhibited favorable intestinal retention and showed no obvious fluorescence accumulation in major organs at this observation time point. Therefore, these findings suggest that AST@MCN-Gel may primarily exert its therapeutic effects locally in the gastrointestinal tract and may help reduce the risk of major organ exposure. Histopathological evaluation of the major organs showed no obvious tissue damage, further supporting the favorable preliminary biosafety of this formulation. H&E staining revealed no evident tissue damage, inflammatory infiltration, or structural abnormalities in the heart, liver, spleen, lungs, or kidneys following treatment, confirming the absence of treatment-related histopathological toxicity (Figure S16). Taken together, these results demonstrate that AST@MCN-Gel exhibits excellent in vivo biocompatibility, pronounced intestinal localization, and minimal off-target organ exposure following oral administration. Combined with its potent anti-inflammatory efficacy and microbiota-modulating capability in DSS-induced IBD, AST@MCN-Gel represents a secure and potent oral therapeutic strategy in the therapy of IBD. AST@MCN-Gel modulates gut microbiota homeostasis in DSS-induced IBD Accumulating evidence has demonstrated that dysregulation of the gut microbiota has a crucial influence on the initiation and advancement of IBD, contributing to epithelial barrier disruption, immune dysregulation, and sustained intestinal inflammation. To elucidate whether AST@MCN-Gel exerts therapeutic effects on IBD through modulation of the gut microbiota, 16 S rRNA gene sequencing was performed to systematically analyze microbial composition and community structure in a DSS-induced IBD mouse model (Fig. 8). Microbial α-diversity analysis revealed that DSS treatment significantly reduced the Chao1 index compared with control group, indicating a marked loss of microbial richness and ecological stability under inflammatory conditions (Fig. 8A). In contrast, AST@MCN-Gel group partially restored microbial richness, suggesting its ability to alleviate DSS-induced microbial depletion. Venn diagram analysis further illustrated that the AST@MCN-Gel group shared a greater number of operational taxonomic units (OTUs) with the control group than with the DSS group, indicating partial normalization of microbial composition following AST@MCN-Gel treatment (Fig. 8B). Principal coordinate analysis (PCoA) based on Bray-Curtis distances demonstrated a clear separation between the DSS group and control group, reflecting profound DSS-induced microbial dysbiosis (Fig. 8C). Notably, the microbial community structure of the AST@MCN-Gel group clustered closer compared to the control group, suggesting that AST@MCN-Gel reshapes the dysbiotic gut microbiota toward a healthier configuration rather than inducing a nonspecific alteration. 16 S ribosomal RNA (rRNA) sequencing analysis of gut microbiota regulated by AST@MCN-Gel. A) Chao1 index reflecting α-diversity (microbial richness). B) Venn diagram illustrating the overlap of shared and unique operational taxonomic units (OTUs) across groups. C) Principal coordinate analysis (PCoA) based on Bray-Curtis dissimilarity, depicting alterations of β-diversity. D) Bar plots of top 30 most abundant genera (relative abundance). E) Phylum-level composition displayed as stacked bar charts. F) Heatmap of differentially abundant families (LEfSe). G) Phylum-level taxonomic composition heatmap (Z-score normalized), with the color gradient indicating high (red) and low (blue) abundance. H) Stacked bar chart of relative abundances for the top 30 genera. Data are presented as mean ± standard deviation. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001 At the genus level, the control group was enriched with beneficial commensals associated with intestinal homeostasis, including Ligilactobacillus, Acidaminobacter, Odoribacter, and Rikenella (Fig. 8D). DSS administration markedly disrupted this microbial balance, characterized by a significant expansion of inflammation-associated genera such as Oscillibacter, along with pronounced alterations in Adlercreutzia and Intestinimonas, reflecting inflammation-driven microbial remodeling. Importantly, AST@MCN-Gel intervention substantially reversed these pathological changes, restoring the relative abundance of Ligilactobacillus and increasing the prevalence of health-associated genera such as Alistipes, Desulfovibrio, and Helicobacter, thereby promoting re-establishment of a balanced microbial ecosystem. Phylogenetic analysis further confirmed that AST@MCN-Gel exerts a targeted regulatory effect on gut microbial composition rather than a generalized perturbation (Fig. 8E). DSS-induced IBD was characterized by the overrepresentation of Bacillota (Firmicutes) and Gammaproteobacteria (Proteobacteria), which are closely associated with metabolic imbalance, epithelial barrier dysfunction, and inflammatory responses [48]. AST@MCN-Gel treatment significantly suppressed the expansion of these inflammation-associated taxa, indicating its role in restraining pathogenic microbial overgrowth and restoring immune homeostasis. At the family level, DSS treatment resulted in a marked increase in potentially pathogenic families, including Bacteroidaceae, Enterobacteriaceae, Tannerellaceae, Muribaculaceae, and Lachnospiraceae. Although Lachnospiraceae is generally considered a butyrate-producing family, its dysregulated expansion has been linked to abnormal energy metabolism in IBD [49]. In particular, the enrichment of Enterobacteriaceae is associated with elevated LPS production, which exacerbates intestinal inflammation. AST@MCN-Gel intervention significantly reduced the abundance of these families, suggesting effective suppression of pro-inflammatory bacteria and reconstruction of a commensal-dominated microbial landscape. Heatmap analysis further visualized these microbial alterations at the phylum level (Fig. 8F). Healthy mice exhibited a balanced microbiota dominated by Bacillota and Bacteroidota, with minimal Pseudomonadota. DSS treatment severely disrupted this balance, leading to a sharp increase in Pseudomonadota, particularly Gammaproteobacteria, along with elevated Deferribacterota and Desulfovibrionia, indicative of increased sulfate-reducing bacteria and epithelial barrier damage. AST@MCN-Gel administration effectively reversed these pathological shifts, reducing Pseudomonadota abundance to near-baseline levels, increasing Bacillota, and enhancing Actinomycetota abundance, consistent with the restoration of bile acid metabolism and microbial functional diversity. Further quantitative analysis revealed that DSS-induced IBD caused a pronounced depletion of unclassified Muribaculaceae, a bacterial family closely associated with polysaccharide fermentation and short-chain fatty acid (SCFA) production (Fig. 8G). AST@MCN-Gel treatment significantly restored the abundance of this family, highlighting its targeted modulatory effect on functionally important commensals within the dysbiotic gut microbiome. Consistently, stacked bar plot analysis of the top 30 genera demonstrated that healthy mice harbored a microbiota enriched in SCFA-producing bacteria, including Blautia, Lachnospiraceae NK4A136 group, Par abacteroides, and Bacteroides, while potentially pathogenic genera such as Escherichia–Shigella, Klebsiella, and Helicobacter were present at low levels (Fig. 8H). DSS markedly increased the abundance of Escherichia–Shigella, induced de novo expansion of Klebsiella, and elevated Desulfovibrio levels by 8.3-fold, likely increasing hydrogen sulfide production and impairing epithelial mitochondrial respiration. Concurrently, the abundance of SCFA-producing bacteria declined sharply. Notably, AST@MCN-Gel intervention significantly suppressed pathogenic bacterial expansion while restoring Blautia and Lachnospiraceae NK4A136 group, and increased Intestinimonas abundance, suggesting recovery of SCFA metabolic capacity and microbial functional diversity. In summary, our results suggest that AST@MCN-Gel may alleviate DSS-induced gut microbiota dysbiosis by inhibiting the proliferation of pro-inflammatory bacteria, restoring the dominance of commensal bacteria, and reshaping intestinal microbial homeostasis. However, it should be noted that, due to the limited animal sample size, the microbiome- and transcriptome-associated analyses in this study should be regarded as exploratory and hypothesis-generating. The related mechanistic conclusions require further validation in independent animal experiments or preclinical studies with larger sample sizes. Conclusion This study presents the establishment of a delivery system for IBD. Exploiting the elevated surface area of MCN, this system efficiently encapsulates free AST, substantially increasing its solubility and bioavailability. In comparison to free AST or MCN alone, the AST@MCN-Gel system demonstrates superior therapeutic efficacy by synergistically modulating inflammation, scavenging intracellular ROS, and protecting macrophages. Further analysis reveals that AST@MCN-Gel facilitates the repolarization of M1 macrophages toward the M2 phenotype, suggesting a potential immune-modulatory role. Moreover, this delivery system effectively restores the intestinal epithelial barrier, reshapes the gut microbiota composition, and reprograms the intestinal immune microenvironment, leading to a substantial reduction in colitis-related symptoms. In DSS-induced IBD mouse models, AST@MCN-Gel outperforms both free AST and MCN alone in terms of therapeutic outcomes. Nevertheless, the present study has certain limitations, including the relatively limited in vivo sample size and the lack of direct pharmacokinetic assessment of AST. Future studies with larger animal cohorts and HPLC or LC–MS/MS-based measurements of AST concentrations in plasma and colonic tissues are needed to validate these findings and better evaluate the local tissue exposure, systemic absorption, and pharmacokinetic behavior of AST@MCN-Gel. In summary, this work marks the first report of MCN as a delivery vehicle for AST, demonstrating their remarkable potential for the treatment of inflammatory diseases. These findings provide compelling evidence for the use of innovative delivery systems in managing inflammatory conditions and pave the way for additional investigation in this promising therapeutic strategy. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Acknowledgements None. Author contributions Conceptualization: Ningli Guo, Jiayi Shi, Tongyao Ji, Kai Li. Methodology: Ningli Guo, Zhang Chen, Hui Xu. Investigation: Xinyu Zhang, Hui Xu, Fengkai Qiu, Ji Ma. Visualization: Ningli Guo, Jiayi Shi, Xinyu Zhang, Zhenyi Wu, Qiaoyou Weng. Funding acquisition: Jingfeng Chen, Xiaojing Wang. administration: Xiaojing Wang, Jingfeng Chen, Zhang Chen. Supervision: Xiaojing Wang, Gaofeng Shu, Qiaoyou Weng, Rongfang Qiu. Writing – original draft: Ningli Guo, Jiayi Shi, Xinyu Zhang. Writing – review & editing: Xiaojing Wang, Jingfeng Chen, Zhang Chen. All authors reviewed the manuscript. Funding This work was supported by the Medical and Health Science and Technology Program of Zhejiang Province (China), (2023RC309, 2024KY1845,2025KY1929); Natural Science Foundation of Zhejiang Province (China), (LLSSY24H160004). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ningli Guo, Jiayi Shi and Xinyu Zhang contributed equally to this work. Contributor Information Zhang Chen, Email: chenzhang861128@163.com. Jingfeng Chen, Email: chenjingfeng1024@sina.com. Xiaojing Wang, Email: wxjing19860818@gmail.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement No datasets were generated or analysed during the current study.